Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
XRP’s $2.16B long bet looks risky – But THIS could change the setup

XRP’s $2.16B long bet looks risky – But THIS could change the setup

AMBCryptoAMBCrypto2026/08/18 00:03
By:AMBCrypto

Going long on Ripple is not the best idea at this stage of the cycle.

From a technical perspective, XRP is already down more than 6% this month and is nowhere close to realizing its gains from July. In contrast, Ethereum has gained a solid 1.7% this month, making it clear that XRP is not attracting big institutional flows. With that said, the chart below becomes even more significant.

Specifically, almost $2.16 billion in fresh long positions have been opened recently, fueling frenzied speculation. Given the technical setup described above, this development makes XRP highly vulnerable to a massive long liquidity sweep.

@media only screen and (min-width: 0px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 50px; transition: min-height 0.3s ease; } } @media only screen and (min-width: 640px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 90px; } }
AD

 

Interestingly, Ripple [XRP] kicked off the week by breaking below the critical $1 level, adding more pressure to the long-heavy setup. If bulls fail to reclaim $1, the breakdown could open the door to deeper downside, a setup that can’t be ignored given the weaker institutional demand.

According to the SoSoValue, XRP ETFs have seen just over $3 million in net inflows so far in August, while Ethereum ETFs have pulled in over $2. That gap shows how much stronger the current capital rotation into ETH has been compared to XRP.

Taken together, the combination of weak technical performance and institutional flows suggests that the large $2.16 billion long bet on XRP looks like a risky trade. If XRP fails to reclaim $1, those leveraged longs could quickly turn into a short-covering squeeze, raising the question: Is Ripple on track for a break below $0.98?

XRP bulls take a risky bet 

One thing to consider when looking at the current bet is the timing of the move.

Notably, while XRP’s technical and institutional setup looks weak, some on-chain signals and liquidity flows are pointing to another direction. One of them is the XRP/ETH ratio, which analysts expect to rebound based on key technical signals. Notably, this is where the chart below begins to hold weight.

According to Token Terminal, RLUSD was the fastest-growing asset over the past seven days, adding $132 million, while Ripple was the faster-growing issuer, also adding $132 million. This suggests that RLUSD supply continues to expand, even as XRP struggles to gain momentum. This divergence is worth watching.

In this context, while $2.16 billion in long positions might seem too risky, the overall setup suggests that XRP bulls may have more conviction behind the trade than the current price action suggests.

Final Summary

  • XRP’s long-squeeze risk has intensified, with over $2.16 billion in long positions recently added.
  • Could XRP bulls be making a strategic bet?
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stock IPO Preview | From Losses to Net Profit of 5.46 Million: The "Three-Dimensional" Platform Business Strategy with a Taste for Golf

Crossing the break-even line, the growth inflection point has arrived.

智通财经•2026/11/11 03:22

Core CPI Exceeds Expectations Again, Fed Hawks Loud! 2027 FOMC Voting Member Directly Calls Inflation Hot

Austan Goolsbee, President of the Chicago Federal Reserve, stated that officials must address the issue of high inflation, and described the October consumer price report as worrisome.

智通财经•2026/11/11 03:06

Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality

The FDA requires all GLP-1 drugs to include a warning about the rare eye disease NAION. Novo Nordisk and Eli Lilly deny any causality, while Citi states that the impact on adoption is limited.

智通财经•2026/11/11 02:56
Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality